Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy.

Inclusion Criteria: 1. Men and women, 18-75 years of age; 2. Participant with a confirmed diagnosis of solid tumor receiving a chemotherapy regimen; 3. Participant experienced thrombocytopenia and chemotherapy delay; 4. ECOG performance status 0-1; Exclusion Criteria: 1. Screening and baseline platelet count\< 30×109/L; 2. Participant has experienced thrombocytopenia due to any etiology other than chemotherapy within 6 months of screening; 3. Participant has any history of hematologic diseases other than chemotherapy-induced thrombocytopenia; 4. Participant has serious bleeding symptoms; 5. Participant has no hepatic metastases, ALT/AST\>3ULN, TBIL\>3ULN; with hepatic metastases, ALT/AST≥5ULN, TBIL≥5ULN; 6. Blood Cr≥1.5ULN or eGFR≤60 ml/min（Cockcroft-Gault）; 7. History of allergy to the study drug; 8. Participant with HIV; 9. Pregnant or lactating women; 10. Other conditions that may affect participant's safety or trial evaluations per investigator's discretion